Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
163.12
-0.76 (-0.46%)
At close: Jun 8, 2026, 4:00 PM EDT
163.12
0.00 (0.00%)
After-hours: Jun 8, 2026, 4:48 PM EDT
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
According to 29 analysts polled by S&P Global, Neurocrine Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $192.88. The average 1-year stock price forecast is 18.24% higher than the current stock price, while the lowest is $144 (-11.72%) and the highest is $250.65 (+53.66%).
Price Target: $192.88 (+18.24%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Neurocrine Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 19 | 20 | 20 | 19 | 20 | 21 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 27 | 28 | 28 | 27 | 28 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 2, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Initiates $213 | Buy | Initiates | $213 | +30.58% | Jun 2, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $180 → $183 | Buy | Maintains | $180 → $183 | +12.19% | May 29, 2026 |
| Bernstein | Bernstein | Buy Initiates $221 | Buy | Initiates | $221 | +35.48% | May 21, 2026 |
| Evercore ISI | Evercore ISI | Buy Maintains $210 | Buy | Maintains | $210 | +28.74% | May 18, 2026 |
Financial Forecast
Revenue This Year
3.77B
from 2.86B
Increased by 31.72%
Revenue Next Year
4.51B
from 3.77B
Increased by 19.60%
EPS This Year
10.27
from 6.39
Increased by 60.64%
EPS Next Year
12.71
from 10.27
Increased by 23.78%
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 4.0B | ||
| Avg | 3.8B | ||
| Low | 3.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 38.9% | ||
| Avg | 31.7% | ||
| Low | 19.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 17.37 | ||
| Avg | 10.27 | ||
| Low | 8.27 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 171.8% | ||
| Avg | 60.6% | ||
| Low | 29.4% |